spravato - Search News

FDA Approves ‘Spravato’ Nasal Spray

Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Monthly Prescribing Reference · 1d

Spravato Approved as Monotherapy for Treatment-Resistant Depression

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.

UPI News on MSN · 4d

FDA approves Spravato, first monotherapy nasal spray to treat depression

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,

J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

Johnson & Johnson's Spravato gains FDA nod to be used as a monotherapy

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

1d

Does Medicare cover ketamine infusions for mental health conditions?

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results